Real-World Studies
Male breast cancer cohort shows 85.3% 5-year survival and no locoregional recurrence
Tepetam et alJournal of Clinical Medicine
Male breast cancer (MBC) remains a rare clinical entity accounting for less than 1% of all breast malignancies, with treatment paradigms largely derived from female breast cancer literature. A retrospective single-center study analyzed 45 patients with histopathologically confirmed MBC treated between and at a tertiary referral center to evaluate clinicopathological features, therapeutic modalities, survival metrics, and prognostic factors.
The cohort demonstrated a median age at diagnosis of 60 years. Invasive ductal carcinoma was the predominant histological subtype, comprising 95.6% of cases. Biomarker profiling revealed high hormone receptor expression, with estrogen receptor (ER) positivity at 93.0% and progesterone receptor (PR) positivity at 95.2%, whereas HER2 overexpression/amplification was identified in 26.8% of patients. Regarding treatment patterns, modified radical mastectomy was executed in 95.6% of patients, while adjuvant therapeutic strategies included endocrine therapy in 88.9%, chemotherapy in 73.3%, and radiotherapy in 64.4%.
At a median follow-up of 84 months (range, 1–125 months), Kaplan–Meier survival analysis yielded an estimated 5-year overall survival (OS) rate of 85.3% and a 5-year disease-free survival (DFS) rate of 68.4%. Notably, no locoregional recurrences were documented in the cohort, with all disease recurrences manifesting as distant metastatic spread. Univariate Cox proportional hazards regression analysis revealed that none of the examined demographic or clinicopathological variables demonstrated a statistically significant association with OS or DFS. These findings support contemporary multimodal treatment approaches while underscoring the need for larger, multicenter collaborative studies to construct male-specific prognostic models.
Key Takeaways
- In a tertiary center cohort of 45 male breast cancer patients followed for a median of 84 months, estimated 5-year overall survival was 85.3% and 5-year disease-free survival was 68.4%.
- No locoregional recurrences occurred across the cohort, as all disease recurrences presented exclusively as distant metastases.
- Univariate Cox proportional hazards regression identified no statistically significant associations between evaluated clinicopathological parameters and overall survival or disease-free survival.
Read the original sourceJournal of Clinical Medicine
